Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Core Insights - Molecular Partners AG and Orano Med have expanded their strategic collaboration to develop a total of ten targeted alpha therapeutics candidates, enhancing their leadership in the field of targeted alpha therapies (TAT) [1][2][9] Collaboration Details - The new agreement includes the development of six additional targeted alpha therapeutics candidates, with Molecular Partners leading the development and Orano Med having the option to co-develop two of these programs [2][3] - The initial agreement in January 2024 involved co-developing four programs, with shared costs and profits, and specific commercialization rights assigned to each company for different programs [3] Technological Synergy - The partnership leverages Molecular Partners' Radio-DARPin platform and Orano Med's expertise in lead-212 (Pb) supply and clinical development, aiming to reduce drug candidate cycle times and enhance the generation of novel drug candidates [4][6] - The collaboration is expected to accelerate the delivery of next-generation targeted alpha therapies to patients, showcasing the strategic synergies between the two companies [6] Financial Outlook - Financial terms of the expanded agreement have not been disclosed, but Molecular Partners anticipates no immediate impact on its financial forecast for fiscal year 2025 and maintains its funding guidance through 2027 [7] Product Development - The most advanced Pb-Radio-DARPin candidate, MP0712, which targets DLL3, is expected to enter first-in-human studies in 2025, pending regulatory approval [3][9] - The Radio-DARPin platform is designed to provide a unique delivery system for radioactive payloads, enhancing targeting capabilities while balancing safety and efficacy [11]